Our Position on

**Planet & Health**

We believe...
that we need **less, better, and greener resources** along the life cycle of medicines and vaccines.

- Climate change is one of the greatest challenges of our age, leading to indirect effects in health and causing an estimated 250,000 additional deaths each year (1).
- Environmental protection is a key to protecting the health of people and we have a responsibility to optimize the environmental profile of our medicines and vaccines along their life cycles.
- An eco-design approach in developing, manufacturing, supplying and dispensing medicines will contribute to make our business model more resilient to environmental challenges.
- Reducing the biopharmaceutical industry’s carbon footprint requires optimized use of renewable energy in manufacturing, sustainable packaging, new factories designed with low environmental footprint and responsible transportation policy for both products and people.
- Innovation contributes to reducing environmental impact in healthcare systems by decarbonizing the patient care pathway, while striving to bring medicines addressing new healthcare challenges caused by rising environmental challenges.

We offer...

a **holistic approach to minimize the impact of our activities and products** on the environment while **helping address climate and environment-related health challenges along the patient’s journey**.

- Bringing innovative science-based solutions to tackle new or existing diseases exacerbated by climate change, especially on heavily affected disease areas such as respiratory diseases, allergies, diabetes, cardiovascular disease, or infectious disease, and actively working with organizations and institutions to provide medicines to patients affected by these diseases.
- We have a positive track record in reducing greenhouse gas emissions related to our activities [29% of reduction compared to 2019(2)], a reduction target of 55% by 2030, and net zero by 2045, in line with our commitment to the Paris Agreements (3).
- Our commitment together with the world’s most influential companies [RE100(4)] is to use 100% renewable across all our global operations by 2030 building the path to carbon neutrality by 2030.
- Top tier internationally recognized scores in water stewardship and in the mitigation of climate change (5), make Sanofi a leader among the companies that are effectively leading the way to a more sustainable future.
- Our commitment is to eco-design all our new products placed on the market by 2025 and have our vaccines packaging blister-free by 2027.
- Our contribution to promoting the design of sustainable patients’ care pathways (6) through our transformative products.
We ask...

for regulatory and financial frameworks that recognize and reward our efforts on reducing our environmental impact.

- Governments to establish mid-term lasting environmental goals that are flexible and predictable to allow sufficient time and resources for organizational, technical, and procedural adaptation.
- Regulators to encourage innovations (even at the post-approval stage) that improve environmental impact by removing regulatory hurdles where possible.
- Payers to develop procurement systems that recognize and reward greener pharmaceutical design and production processes.
- Investors to incentivize environmental efforts and work in collaboration with pharmaceutical companies to harmonize standards in the measurement of sustainability performance.

Footnote:

(1) https://www.who.int/news-room/fact-sheets/detail/climate-change-and-health
(2) Scope 1 and Scope 2 emission data included in the 2020 Universal Registration Document
(3) Approval from the “Science Based Targets initiative” (SBTi) to reduce absolute* greenhouse gas emissions in line with the objective of the 2015 Paris Agreement
(4) www.there100.org
(5) CDP: Disclosure Insight Action
(6) Sanofi leads the patient care pathway decarbonization workstream of the Sustainable Markets Initiative Health Systems Taskforce